Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Julphar
Johnson and Johnson
Argus Health
Healthtrust
Chubb
Deloitte
Chinese Patent Office
Fuji

Generated: January 18, 2018

DrugPatentWatch Database Preview

Taro Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM, and what generic alternatives to TARO PHARM drugs are available?

TARO PHARM has thirty-nine approved drugs.

There are three US patents protecting TARO PHARM drugs. There are two tentative approvals on TARO PHARM drugs.

There are twenty-five patent family members on TARO PHARM drugs in thirteen countries and twenty-two supplementary protection certificates in nine countries.

Summary for Taro Pharm
International Patents:25
US Patents:3
Tradenames:36
Ingredients:33
NDAs:39

Drugs and US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharms North INFANTS' FEVERALL acetaminophen SUPPOSITORY;RECTAL 018337-004 Aug 26, 1992 OTC Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm FELBAMATE felbamate TABLET;ORAL 207093-001 Apr 20, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm CIPROFLOXACIN HYDROCHLORIDE ciprofloxacin hydrochloride TABLET;ORAL 076912-001 Feb 18, 2005 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharms North ACETAMINOPHEN acetaminophen SUPPOSITORY;RECTAL 018337-001 Approved Prior to Jan 1, 1982 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm WARFARIN SODIUM warfarin sodium TABLET;ORAL 040301-008 Jul 15, 1999 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm WARFARIN SODIUM warfarin sodium TABLET;ORAL 040301-009 Jul 15, 1999 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm Inds FLUTICASONE PROPIONATE fluticasone propionate OINTMENT;TOPICAL 077145-001 Jun 14, 2005 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm Inds AMCINONIDE amcinonide CREAM;TOPICAL 076229-001 May 31, 2002 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm Inds CARBAMAZEPINE carbamazepine TABLET, CHEWABLE;ORAL 075687-002 Jul 29, 2002 RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm Inds LAMOTRIGINE lamotrigine TABLET;ORAL 078525-002 Jan 27, 2009 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 3/16/2011

Non-Orange Book US Patents for Taro Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,039,657 Process for preparing malathion for pharmaceutical use ➤ Subscribe
8,536,155 Process for preparing malathion for pharmaceutical use ➤ Subscribe
8,957,238 Process for preparing malathion for pharmaceutical use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Taro Pharm Drugs

Supplementary Protection Certificates for Taro Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00617 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
C0012 France ➤ Subscribe PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
401 Luxembourg ➤ Subscribe PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
C/GB08/005 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
00085 Netherlands ➤ Subscribe PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
C0067 France ➤ Subscribe PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
13/044 Ireland ➤ Subscribe PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
C0014 France ➤ Subscribe PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
C/GB02/033 United Kingdom ➤ Subscribe PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2013 00053 Denmark ➤ Subscribe PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Covington
Cerilliant
Baxter
Medtronic
Daiichi Sankyo
Cantor Fitzgerald
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot